Drug Trial Radar · NCT00767000
Dose Range Finding Study of MK-0941 in Patients With Type 2 Diabetes Mellitus on Insulin (MK-0941-007 AM3 EXT1 AM1)(TERMINATED)
Last checked: Nov 19, 2026Latest source record: Feb 19, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
813
Actual
Start
Oct 2008
Primary completion
Apr 2010
Study completion Jun 2010
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Oct 6, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 21 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to test the effect of MK-0941 as add-on therapy for participants taking insulin for type 2 diabetes mellitus. The primary hypotheses of this study are that treatment with MK-0941 added to insulin will provide greater reduction in hemoglobin A1c (HbA1c) level than will placebo added to insulin at 14 weeks, and that MK-0941 will be well-tolerated at 1 or more doses that demonstrate efficacy.
Conditions
- Diabetes Mellitus, Type 2
Interventions
MK-0941Drug
MK-0941 tablets three times daily
Comparator: PlaceboDrug
Matching placebo to MK-0941 three times daily
LantusBiological
Lantus injection once daily
MetforminDrug
Metformin ≥1500 mg/day at a stable dose for at least 6 weeks before Screening and for the duration of the study. The number of randomized participants who receive metformin will be capped at 70% of enrollment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Hemoglobin A1c (HbA1c) LevelTime frame: Baseline and Weeks 14, 54, 106, and 158
- Percentage of Participants Who Experienced at Least One Adverse EventTime frame: Entire study including 54-week study and 104-week extension
- Percentage of Participants Who Discontinued Study Medication Due to an Adverse EventTime frame: Entire study including 54-week study and 104-week extension
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.